Prevalence and outcome of post-transfusion hepatitis C acquired at different ages and detected in look-back screening. (3rd July 2018)

• Record Type: Journal Article
• Authors: Millbourn, Charlotta; Psaros Einberg, Afrodite; Lindh, Gudrun; Hökeberg, Ingegerd; Fischler, Björn; Lindahl, Karin
• Is Part Of: Scandinavian journal of gastroenterology. Volume 53:Number 7(2018)
• Page Start: 870
• Page End: 875
• Publication Date: 2018-07-03
• Subjects: Hepatitis C -- virus infection -- blood transfusion -- prevalence -- anti-viral treatment; Gastroenterology -- Periodicals; Digestive organs -- Diseases -- Periodicals; 616.33
• DOI: 10.1080/00365521.2018.1476911
• Languages: English
• ISSNs: 0036-5521

Abstract

Abstract: Objectives: The prevalence of hepatitis C virus (HCV) infection in Sweden is estimated to 0.5%. Before 1992, blood transfusion posed a risk of HCV transmission. The primary aim of this study was to estimate anti-HCV prevalence in Stockholm County among individuals receiving blood transfusions 1965–1991. The secondary aim was to study the effect of age at transfusion on the development of liver disease and treatment outcome. Materials and methods: This is a retrospective analysis of individuals found to be anti-HCV tested positive in Stockholm County during a national screening campaign in Sweden 2008–2010. All anti-HCV-positive individuals were also HCV RNA tested. Data on age at transfusion, age at diagnosis, HCV genotype, viral load, fibrosis score, liver histology and antiviral treatment were recorded. Results: Out of 7473, 134 (1.8%) tested individuals were anti-HCV positive and 102 were HCV RNA positive resulting in a prevalence of chronic hepatitis C (CHC) of 1.4%. The rate of advanced liver damage was 18% (10/56). Patients younger than 19 years of age at transfusion were significantly more often started on antiviral treatment compared to adult patients, 65% vs 29% p < .001. No significant correlation was found between treatment outcome and gender or age at transfusion. Conclusions: In this study, we found an anti-HCV prevalence of 1.8% which is considerably higher than the estimated prevalence in the Swedish general population (0.5%), and patients infected during childhood were more likely to receive antiviral treatment. Additional data on the HCV epidemic in Sweden are needed regarding prevalence and age distribution.